Smithkline Beecham

Bioxodes Appoints Industry Veteran Philippe Monteyne as Chairman to Advance Breakthrough Stroke Therapy BIOX-101

- Bioxodes has appointed Philippe Monteyne, MD, PhD, a former GSK and Sanofi executive with extensive neurological expertise, as chairman of its Board of Directors to guide development of breakthrough stroke candidate BIOX-101. - The company's lead asset BIOX-101 showed encouraging Phase 2a results in intracerebral hemorrhage, with all treated patients experiencing hematoma reduction and improved functional outcomes compared to standard care. - A potentially registrational Phase 2b trial scheduled for 2027 could be sufficient for conditional marketing authorization submissions in the U.S. and Europe, targeting commercialization as early as 2030. - BIOX-101 represents a first-in-class anticoagulant derived from tick saliva that reduces clotting without increasing bleeding, addressing a critical unmet need in hemorrhagic stroke where no approved therapies currently exist.